Paulo Vidal Campregher
Overview
Explore the profile of Paulo Vidal Campregher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gava F, Campregher P, Tomaz V, Candido M, Petroni R, Chahud F, et al.
Pediatr Blood Cancer
. 2024 Sep;
71(12):e31346.
PMID: 39307989
No abstract available.
2.
Alves de Souza G, Dornellas D, Campregher P, Teixeira C, Schvartsman G
Oncologist
. 2024 Jun;
29(9):764-767.
PMID: 38832711
Comprehensive genomic profiling is highly recommended for treatment decision in nonsquamous, non-small cell lung cancer (NSCLC). However, rare genomic alterations are still being unveiled, with scarce data to guide therapy....
3.
Vince C, Brassesco M, Mancano B, Gregianin L, Carbone E, do Amaral E Castro A, et al.
JCO Precis Oncol
. 2024 May;
8:e2300713.
PMID: 38810175
Purpose: Our study aimed to explore real-world treatment scenarios for children and adolescents with neurotrophic tropomyosin receptor kinase (NTRK)-fused tumors, emphasizing access, responses, side effects, and outcomes. Patients And Methods:...
4.
Pardo I, Fagundes P, Oliveira R, Campregher P
Einstein (Sao Paulo)
. 2024 Feb;
22:eRW0552.
PMID: 38324848
Introduction: Triple-negative breast cancer is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This phenotype...
5.
da Rosa S, de Lima L, Silveira C, Cortes L, Oliveira Filho J, de Souza Reis R, et al.
Clin Transl Oncol
. 2023 May;
25(12):3431-3436.
PMID: 37165281
Background: Acute myeloid leukemia (AML) is a myeloid neoplasm associated with a high morbidity and mortality. The diagnosis, risk stratification and therapy selection in AML have changed substantially in the...
6.
Dias L, Pereira C, Centuriao N, Nascimento J, Ribeiro A, Hamerschlak N, et al.
Einstein (Sao Paulo)
. 2023 Jan;
21:eAO0100.
PMID: 36629680
Objective: To analyze the karyotype test and myeloid panel with next-generation sequencing findings in patients with myelofibrosis, and to compare transplant characteristics in patients referred for bone marrow transplantation. Methods:...
7.
Horak P, Griffith M, Danos A, Pitel B, Madhavan S, Liu X, et al.
Genet Med
. 2022 Sep;
24(9):1991.
PMID: 36063163
No abstract available.
8.
Sperandio R, Luiza Teixeira Tostes F, Campregher P, Paes V, Moura F, Schvartsman G
Lung Cancer
. 2022 Mar;
166:94-97.
PMID: 35245845
Comprehensive next-generation sequencing panels are leading to detection of rare gene fusion events. EFGR-RAD51 fusion is a rare oncogenic finding and clinical data for management of this condition is scarce....
9.
Horak P, Griffith M, Danos A, Pitel B, Madhavan S, Liu X, et al.
Genet Med
. 2022 Feb;
24(5):986-998.
PMID: 35101336
Purpose: Several professional societies have published guidelines for the clinical interpretation of somatic variants, which specifically address diagnostic, prognostic, and therapeutic implications. Although these guidelines for the clinical interpretation of...
10.
Bezinelli L, Eduardo F, Ferreira M, Gobbi M, de Castro F, Dos Santos G, et al.
J Dermatol
. 2021 May;
48(8):e395-e396.
PMID: 34036626
No abstract available.